BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 23337984)

  • 21. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 22. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
    J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
    Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
    Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.
    Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J
    Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
    Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
    J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
    Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
    Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
    Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells.
    Hong SH; Jeong JS; Lee YJ; Jung HI; Cho KS; Kim CM; Kwon BS; Sullenger BA; Lee SW; Kim IH
    Mol Ther; 2008 Jan; 16(1):74-80. PubMed ID: 17700543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
    Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
    Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mannan-modified adenovirus as a vaccine to induce antitumor immunity.
    Ding ZY; Wu Y; Luo Y; Su JM; Li Q; Zhang XW; Liu JY; He QM; Yang L; Tian L; Zhao X; Deng HX; Wen YJ; Li J; Kang B; Wei YQ
    Gene Ther; 2007 Apr; 14(8):657-63. PubMed ID: 17287861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
    Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine.
    Wang Y; Zhang J; Wu Y; Ding ZY; Luo XM; Liu J; Zhong WN; Deng GH; Xia XY; Deng YT; Wei YQ; Jiang Y
    Sci Rep; 2015 Jun; 5():11275. PubMed ID: 26085010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
    Kim JE; Jin DH; Lee WJ; Hur D; Wu TC; Kim D
    Pharmacol Res; 2013 May; 71():23-33. PubMed ID: 23428347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
    Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
    J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.